Dale J. Calleja
Parkville, VIC, Australia
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 15 publications
Global analysis of cancer cell responses to USP9X inhibition.
Journal: The EMBO journal
Published: June 09, 2025
A novel PLpro inhibitor improves outcomes in a pre-clinical model of long COVID.
Journal: Nature communications
Published: December 18, 2024
Characterisation of the OTU domain deubiquitinase complement of Toxoplasma gondii.
Journal: Life science alliance
Published: September 05, 2022
Protein kinase R is an innate immune sensor of proteotoxic stress via accumulation of cytoplasmic IL-24.
Journal: Science immunology
Published: February 11, 2022
Insights Into Drug Repurposing, as Well as Specificity and Compound Properties of Piperidine-Based SARS-CoV-2 PLpro Inhibitors.
Journal: Frontiers in chemistry
Published: January 24, 2022
Discovery of an exosite on the SOCS2-SH2 domain that enhances SH2 binding to phosphorylated ligands.
Discovery of an exosite on the SOCS2-SH2 domain that enhances SH2 binding to phosphorylated ligands.
Journal: Nature communications
Published: April 11, 2021
Mechanism and inhibition of the papain-like protease, PLpro, of SARS-CoV-2.
Journal: The EMBO journal
Published: July 17, 2020
NLRP1 variant M1184V decreases inflammasome activation in the context of DPP9 inhibition and asthma severity.
Journal: The Journal of allergy and clinical immunology
Published: February 06, 2020
Last Updated: 09/26/2026